CBT 102A
Alternative Names: CBT102-ALatest Information Update: 15 Mar 2026
At a glance
- Originator Hedu Biotechnology (Shanghai)
- Class Bacteria; Gene therapies; Probiotics
- Mechanism of Action Bacteria replacements; Gastrointestinal microbiome modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase 0 Phenylketonuria
Most Recent Events
- 07 Mar 2024 Children's Hospital of Fudan University and Hedu Biotechnology completes a phase 0 trial in Phenylketonuria (In children, In adolescents) in China (PO) (NCT05948020)
- 02 Sep 2023 Phase 0 clinical trials in Phenylketonuria (In children, In adolescents) in China (PO) (NCT05948020)
- 25 Jul 2023 Hedu Biotechnology (Shanghai) plans clinical trial for Phenylketonuria (In children, In adolescents) (PO) (NCT05948020)